At the beginning of the month, AbbVie completed its $63B acquisition of Ireland-based manufacturer Allergan, a deal the largest of its kind since Bristol-Myers Squibb acquired Celgene for $74B last year. With this partnership, Allergan’s extensive portfolio will complement AbbVie’s focus on haematologic oncology, also making AbbVie the fourth largest pharmaceutical company by revenue.

The company predicts its yearly revenues to reach $50B as a consequence of its diversified on-market portfolio. Read more here.